NASDAQ:FIXX Homology Medicines (FIXX) Stock Price, News & Analysis → the most reliable asset on earth is making a comeback (From DTI) (Ad) Free FIXX Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range$0.29▼$0.9352-Week Range N/AVolume401,467 shsAverage Volume249,289 shsMarket Capitalization$54.33 millionP/E RatioN/ADividend YieldN/APrice Target$2.13 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Homology Medicines alerts: Email Address Homology Medicines MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside∞ Upside$2.13 Price TargetShort InterestHealthy0.81% of Float Sold ShortDividend StrengthN/ASustainability-0.33Upright™ Environmental ScoreNews Sentiment0.47Based on 4 Articles This WeekInsider TradingSelling Shares$11,581 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.75) to ($0.70) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.22 out of 5 starsMedical Sector165th out of 939 stocksPharmaceutical Preparations Industry64th out of 431 stocks 3.3 Analyst's Opinion Consensus RatingHomology Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.13, Homology Medicines has a forecasted upside of ∞ from its current price of $0.00.Amount of Analyst CoverageHomology Medicines has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.81% of the float of Homology Medicines has been sold short.Short Interest Ratio / Days to CoverHomology Medicines has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Homology Medicines has recently increased by 5.09%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldHomology Medicines does not currently pay a dividend.Dividend GrowthHomology Medicines does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreHomology Medicines has received a 78.74% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Homology Medicines is -0.33. Previous Next 2.5 News and Social Media Coverage News SentimentHomology Medicines has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Homology Medicines this week, compared to 1 article on an average week.Search InterestOnly 8 people have searched for FIXX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Homology Medicines to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Homology Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,581.00 in company stock.Percentage Held by Insiders16.10% of the stock of Homology Medicines is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 31.32% of the stock of Homology Medicines is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Homology Medicines are expected to grow in the coming year, from ($0.75) to ($0.70) per share. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIthe most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.And you can see how it works for FREE when you Click Here About Homology Medicines Stock (NASDAQ:FIXX)Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.Read More Ad DTIthe most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.And you can see how it works for FREE when you Click Here FIXX Stock News HeadlinesMarch 24, 2024 | finanznachrichten.deHomology Medicines, Inc.: Homology Medicines Declares Distribution to Common StockholdersMarch 23, 2024 | seekingalpha.comFIXX Homology Medicines, Inc.March 28, 2024 | Behind the Markets (Ad)4x Better than Bitcoin4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 20, 2024 | americanbankingnews.comHomology Medicines, Inc. (NASDAQ:FIXX) Sees Significant Increase in Short InterestMarch 18, 2024 | finance.yahoo.comHomology Medicines Declares Distribution to Common StockholdersFebruary 27, 2024 | businesswire.comHOMOLOGY MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Homology Medicines, Inc. - FIXXFebruary 2, 2024 | investing.comHomology Medicines Inc (FIXX)January 4, 2024 | finanznachrichten.deHomology Medicines, Inc.: Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price DeficiencyMarch 28, 2024 | Behind the Markets (Ad)4x Better than Bitcoin4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.January 4, 2024 | msn.comHomology Medicines gets non-compliance notice from NasdaqJanuary 3, 2024 | finance.yahoo.comHomology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price DeficiencyDecember 27, 2023 | benzinga.comHomology Medicines Stock (NASDAQ:FIXX) Insider TradesDecember 27, 2023 | benzinga.comHomology Medicines Stock (NASDAQ:FIXX), Short Interest ReportNovember 21, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MIRO, SRC, PATI, FIXXNovember 17, 2023 | businesswire.comHOMOLOGY MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Homology Medicines, Inc. - FIXXNovember 17, 2023 | businesswire.comHOMOLOGY MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Homology Medicines, Inc. - FIXXNovember 17, 2023 | bizjournals.comBig Pharma-backed startup to go public by merging with gutted HomologyNovember 16, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Homology Medicines (FIXX), Align Tech (ALGN) and Calidi Biotherapeutics (CLDI)November 16, 2023 | msn.comHomology Medicines slumps after merger deal with Q32 BioNovember 16, 2023 | msn.comWhy Is Rare Disease Focused Homology Medicines Stock Trading Lower Today?November 16, 2023 | tmcnet.comFIXX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Homology Medicines, Inc. Is Fair to ShareholdersNovember 16, 2023 | marketwatch.comHomology Medicines Shares Drop 38% After Buyout Offer From Q32 BioNovember 16, 2023 | markets.businessinsider.comHomology Medicines To Merge With Q32 Bio; Homology Medicines Down In Pre-marketNovember 16, 2023 | finance.yahoo.comQ32 Bio and Homology Medicines Announce Merger AgreementNovember 15, 2023 | finanznachrichten.deHomology Medicines, Inc.: Homology Medicines Reports Third Quarter 2023 Financial ResultsNovember 14, 2023 | msn.comHomology Medicines GAAP EPS of -$0.57 misses by $0.15November 14, 2023 | finance.yahoo.comHomology Medicines Reports Third Quarter 2023 Financial ResultsSee More Headlines Receive FIXX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Homology Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today3/27/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:FIXX CUSIPN/A CIK1661998 Webwww.homologymedicines.com Phone(781) 301-7277FaxN/AEmployees7Year Founded2015Price Target and Rating Average Stock Price Target$2.13 High Stock Price Target$3.50 Low Stock Price Target$0.75 Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-112,960,000.00 Net Margins-4,779.31% Pretax Margin-7,532.87% Return on Equity-102.52% Return on Assets-74.91% Debt Debt-to-Equity RatioN/A Current Ratio7.25 Quick Ratio7.25 Sales & Book Value Annual Sales$1.16 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.26 per share Price / BookN/AMiscellaneous Outstanding Shares58,130,000Free Float48,774,000Market Cap$54.33 million OptionableOptionable Beta-0.10 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Paul Alloway J.D. (Age 52)Ph.D., President & COO Comp: $661.45kDr. Saswati Chatterjee Ph.D.Co-Founder & Member of Scientific Advisory BoardMr. Charles Michaud Jr.CPA, VP of Finance, Corporate Controller & TreasurerMs. Theresa McNeely (Age 60)Chief Communications Officer & Patient Advocate Key CompetitorsCleneNASDAQ:CLNNAadi BioscienceNASDAQ:AADIReneo PharmaceuticalsNASDAQ:RPHMNextCureNASDAQ:NXTCRallybioNASDAQ:RLYBView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 106,852 shares on 3/11/2024Ownership: 3.355%Vanguard Group Inc.Sold 106,852 shares on 2/15/2024Ownership: 3.355%Newtyn Management LLCBought 1,399,260 shares on 2/15/2024Ownership: 2.420%ADAR1 Capital Management LLCBought 293,676 shares on 2/14/2024Ownership: 0.508%George Kaiser Family FoundationBought 267,194 shares on 2/12/2024Ownership: 0.530%View All Insider TransactionsView All Institutional Transactions FIXX Stock Analysis - Frequently Asked Questions Should I buy or sell Homology Medicines stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Homology Medicines in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" FIXX shares. View FIXX analyst ratings or view top-rated stocks. What is Homology Medicines' stock price target for 2024? 2 equities research analysts have issued 1 year target prices for Homology Medicines' stock. Their FIXX share price targets range from $0.75 to $3.50. On average, they anticipate the company's share price to reach $2.13 in the next year. View analysts price targets for FIXX or view top-rated stocks among Wall Street analysts. When is Homology Medicines' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our FIXX earnings forecast. How were Homology Medicines' earnings last quarter? Homology Medicines, Inc. (NASDAQ:FIXX) issued its quarterly earnings results on Monday, November, 15th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.30) by $0.03. The company had revenue of $1.68 million for the quarter, compared to analysts' expectations of $0.63 million. Homology Medicines had a negative net margin of 4,779.31% and a negative trailing twelve-month return on equity of 102.52%. When did Homology Medicines' stock split? Shares of Homology Medicines split on the morning of Wednesday, March 20th 2024. The 2-1 split was announced on Wednesday, March 20th 2024. The newly minted shares were payable to shareholders after the market closes on Wednesday, March 20th 2024. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. What other stocks do shareholders of Homology Medicines own? Based on aggregate information from My MarketBeat watchlists, some companies that other Homology Medicines investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Gossamer Bio (GOSS), Spero Therapeutics (SPRO), Alector (ALEC), Dynavax Technologies (DVAX), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO). When did Homology Medicines IPO? Homology Medicines (FIXX) raised $100 million in an initial public offering on Wednesday, March 28th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI acted as the underwriters for the IPO and BTIG was co-manager. Who are Homology Medicines' major shareholders? Homology Medicines' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.36%), Vanguard Group Inc. (3.36%), Newtyn Management LLC (2.42%), BML Capital Management LLC (1.29%), George Kaiser Family Foundation (0.53%) and ADAR1 Capital Management LLC (0.51%). Insiders that own company stock include Albert Seymour, Arthur Tzianabos, Julie Jordan, Michael Lee Blum, Paul Alloway, Timothy P Kelly and W Bradford Smith. View institutional ownership trends. How do I buy shares of Homology Medicines? Shares of FIXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FIXX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Homology Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.